Literature DB >> 110833

Selective depression of the xenogeneic cell-mediated lympholysis in systemic lupus erythematosus.

B Charpentier, C Carnaud, J F Bach.   

Abstract

The immunological responsiveness of a panel of 17 patients with systemic lupus erythematosus (SLE) was studied in an in vitro model of xenogeneic sensitization against mouse lymphoid cells. Generation of cytotoxic thymus-derived (T) cells evaluated by a chromium release assay against labeled target cells was found to be drastically impaired in these lupus patients. Such depression was independent of drug therapy at the time of the study, clinical status, and other immunological parameters such as antibodies against native DNA, complement levels, cryoglobulinemia, circulating immune complexes, or T- and bone marrow-derived (B)-cell numbers. In contrast to the cytotoxic response, the proliferative responses to phytohemagglutinin, to allogeneic lymphocytes, and to xenogeneic lymphocytes were not significantly different from those of normal individuals. The latter response was shown to be H-2 restricted with the primed lymphocyte test. These results suggest the presence of a selective defect in the generation or in the expression of killer cells rather than a deficiency in antigen recognition by T cells. The role of serum factor(s) was examined by educating the lymphocytes of normal subjects in the presence of serum from SLE patients. Such manipulation affected both the generation of killer cells and the proliferative response. Finally our observations indicate that depression of cell-mediated immunity in SLE patients may be associated with several mechanisms including a cellular one, specifically affecting the generation of killer T cells, and a humoral one possibly as a result of antilymphocytic antibodies and(or) immune complexes.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 110833      PMCID: PMC372126          DOI: 10.1172/JCI109469

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  47 in total

1.  Lymphocyte responsiveness in systemic lupus erythematosus.

Authors:  P D Utsinger
Journal:  Arthritis Rheum       Date:  1976 Jan-Feb

Review 2.  AUTOANTIBODIES AND DISEASE.

Authors:  H G KUNKEL; E M TAN
Journal:  Adv Immunol       Date:  1964       Impact factor: 3.543

3.  Dose-dependent hyporreactivity to phytohemagglutinin in systemic lupus erythematosus.

Authors:  I Malavé; Z Layrisse; M Layrisse
Journal:  Cell Immunol       Date:  1975-02       Impact factor: 4.868

4.  A relationship between impaired cellular immunity humoral suppression of lymphocyte function and severity of systemic lupus erythematosus.

Authors:  D A Horwitz; J B Cousar
Journal:  Am J Med       Date:  1975-06       Impact factor: 4.965

5.  The role of the Fc receptor (FcR) of thymus-derived lymphocytes. I. Presence of FcR on cytotoxic lymphocytes and absence of direct role in cytotoxicity.

Authors:  J C Leclerc; C Plater; W H Fridman
Journal:  Eur J Immunol       Date:  1977-08       Impact factor: 5.532

6.  Impaired cell-mediated immunity in systemic lupus erythematosus (SLE). A controlled study of 23 untreated patients.

Authors:  J G Paty; C W Sienknecht; A S Townes; A S Hanissian; J B Miller; A T Masi
Journal:  Am J Med       Date:  1975-12       Impact factor: 4.965

7.  Lymphocyte-mediated cytotoxicity: effects of ageing, adult thymectomy and thymic factor.

Authors:  M A Bach
Journal:  J Immunol       Date:  1977-08       Impact factor: 5.422

8.  The Fc receptor on thymus-derived lymphocytes. III. Mixed lymphocyte reactivity and cell-mediated lympholytic activity of Fc- and Fc+ T lymphocytes.

Authors:  R D Stout; S D Waksal; L A Herzenberg
Journal:  J Exp Med       Date:  1976-07-01       Impact factor: 14.307

9.  Immunoregulatory circuits among T-cell sets. II. Physiologic role of feedback inhibition in vivo: absence in NZB mice.

Authors:  H Cantor; L McVay-Boudreau; J Hugenberger; K Naidorf; F W Shen; R K Gershon
Journal:  J Exp Med       Date:  1978-04-01       Impact factor: 14.307

10.  Genetic and cellular aspects of xenogeneic mixed leukocyte culture reaction.

Authors:  K F Lindahl; F H Bach
Journal:  J Exp Med       Date:  1976-08-01       Impact factor: 14.307

View more
  8 in total

1.  Both perforin and FasL are required for optimal CD8 T cell control of autoreactive B cells and autoantibody production in parent-into-F1 lupus mice.

Authors:  Kateryna Soloviova; Maksym Puliaiev; Roman Puliaev; Irina Puliaeva; Charles S Via
Journal:  Clin Immunol       Date:  2018-06-22       Impact factor: 3.969

Review 2.  The use of monoclonal anti-T cell antibodies to study T cell imbalances in human diseases.

Authors:  M A Bach; J F Bach
Journal:  Clin Exp Immunol       Date:  1981-09       Impact factor: 4.330

3.  Studies on T cell subsets and functions in leprosy.

Authors:  M A Bach; L Chatenoud; D Wallach; F Phan Dinh Tuy; F Cottenot
Journal:  Clin Exp Immunol       Date:  1981-06       Impact factor: 4.330

4.  Natural killer cells and interferon responses in patients with systemic lupus erythematosus.

Authors:  G C Tsokos; A H Rook; J Y Djeu; J E Balow
Journal:  Clin Exp Immunol       Date:  1982-11       Impact factor: 4.330

5.  Interleukin-1-production by monocytes from patients with systemic lupus erythematosus.

Authors:  S Sierakowski; E J Kucharz; R W Lightfoot; J S Goodwin
Journal:  Clin Rheumatol       Date:  1987-09       Impact factor: 2.980

6.  Impaired T cell capping and receptor regeneration in active systemic lupus erythematosus. Evidence for a disorder intrinsic to the T lymphocyte.

Authors:  G M Kammer
Journal:  J Clin Invest       Date:  1983-11       Impact factor: 14.808

7.  Cytotoxic responses to alloantigens in systemic lupus erythematosus.

Authors:  G C Tsokos; J E Balow
Journal:  J Clin Immunol       Date:  1981-10       Impact factor: 8.317

8.  Defect in the generation of cytotoxic T cells in lepromatous leprosy.

Authors:  J L Stach; M Strobel; F Fumoux; J F Bach
Journal:  Clin Exp Immunol       Date:  1982-06       Impact factor: 4.330

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.